<DOC>
	<DOCNO>NCT00127127</DOCNO>
	<brief_summary>The primary purpose trial determine maximum tolerate dose ( MTD ) , maximum acceptable dose ( MAD ) evaluate dose limit toxicity ( DLT ) oral suberoylanilide hydroxamic acid patient solid tumor .</brief_summary>
	<brief_title>A Study Oral Suberoylanilide Hydroxamic Acid ( SAHA ) Patients With Solid Tumors ( 0683-029 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients histologically cytologically diagnose solid tumor ; standard therapy available patient fail respond standard therapy Patients history immunotherapy , radiotherapy , surgery , chemotherapy previous 4 week ; previous treatment 5 chemotherapeutic regimen . Any uncontrolled concomitant illness Are pregnant breastfeed Serious drug food allergy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>